KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Intangibles (2017 - 2025)

BeOne Medicines (ONC) reported Change in Intangibles of $20.0 million for Q2 2025, up 327.9% on a QoQ basis from $4.7 million in Q1 2024.

BeOne Medicines (ONC) has 5 years of Change in Intangibles data on file, last reported at $20.0 million in Q2 2025.

  • Quarterly Change in Intangibles changed N/A year-over-year to $20.0 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was $20.0 million (up 327.9% YoY) and the FY2025 annual result came in at $20.0 million, up 327.9% from the prior year.
  • Change in Intangibles advanced to $20.0 million in Q2 2025 per ONC's latest filing, from $4.7 million in the prior quarter.
  • Across five years, Change in Intangibles topped out at $20.0 million in Q2 2025 and bottomed at $4.7 million in Q1 2024.
  • The 3-year median for Change in Intangibles is $9.7 million (2023), against an average of $11.0 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Intangibles (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 68,980.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 BeOne Medicines - - 1.35 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 20.00 Mn
Jun 30, 2025 20.00 Mn
Mar 31, 2024 4.67 Mn
Mar 31, 2024 4.67 Mn
Dec 31, 2023 9.95 Mn
Dec 31, 2023 9.95 Mn
Sep 30, 2023 9.41 Mn
Sep 30, 2023 9.41 Mn
Dec 31, 2018 332,000.00
Dec 31, 2018 332,000.00
Sep 30, 2018 612,000.00
Sep 30, 2018 612,000.00
Sep 30, 2017 -12.12 Mn
Sep 30, 2017 -12.12 Mn